| *Together with VantagePoint & Brownstone Research | Good day, 360! | Here are some of our top movers today. And don't forget to join us in Market Masters - the hottest trading room around 🔥. Be the best prepared trader on the Street! | | FOCUS LIST🔎 | GRO - Up over 75% in pre after signing memorandum of understanding for ~$200m power line construction and $20m investment with Fictor Energia | XAGE - Up over 100% in pre after announcing merger with THPlasma and termination of 20/20 BioLabs transaction | SXTP - Up over 75% in pre after announcing potential human Babesiosis market size for ARAKODA® (tafenoquine): annual max TAM, sales of $245 million; cumulative through patent expiration, $1.1 billion | | *together with VantagePoint | Did You Miss Yesterday? | Don't Sweat It! | Brand New A.I. Trading Summit Coming Up! | | → Your Invitation's On This Page. | Don't Miss The Next A.I. Powered Trades! |
|
| | HOTLIST🔥 | GRO - Up over 75% in pre after signing memorandum of understanding for ~$200m power line construction and $20m investment with Fictor Energia | Brazil Potash Corp. (GRO) engages in the exploration and development of potash properties in Brazil. The company holds interest in the Autazes project located in the state of Amazonas, Brazil. | In the after-hours yesterday, the company announced the signing of a non-binding Memorandum of Understanding (MOU) with Fictor & WTT S.A., part of the infrastructure division of Fictor Group, a leading Brazilian private equity firm. | The MOU outlines terms for Fictor Energia to fund ~$200 million in power transmission construction costs for the Autazes Project while securing long-term energy supply and a $20 million strategic equity investment. | Energia plans to invest $20 million equity into Brazil Potash in two tranches: 1) $2 million upon signing of the definitive partnership agreement; and 2) $18 million upon receipt of the power line installation license. | The power transmission infrastructure would be expected to be completed and operational by July 2029, aligning with the Autazes Project's planned production timeline. | Shares of GRO traded up over 75% in the pre-market in reaction to the news. | | The $2.20 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.60, $2.85 and then the after-hours high at $2.97. Beyond that, $3.10 and $3.60 come into play. | Below $2.20, targets to the downside are $2.05, $1.70, $1.55 and then a gap fill at $1.45. | | XAGE - Up over 100% in pre after announcing merger with THPlasma and termination of 20/20 BioLabs transaction | Longevity Health Holdings, Inc. (XAGE) is a company focused on human longevity and healthy aging. | In the after-hours yesterday, the company announced the execution of a definitive merger agreement with True Health Inc., a leading player in the fast growing plasma collection industry under the THPlasma brand ("THPlasma"), to combine the companies in an all-stock transaction. | Following the closing of the Merger, the combined company is expected to continue to trade on Nasdaq under the symbol "XAGE." | THPlasma operates a chain of plasma collection centers in the Northeast United States. The Company has long-term partnerships with key Industry players for guaranteed sales offtake up to $100 million per year. | Shares of XAGE traded up over 100% in the pre-market in reaction to the news. | | The $4.50 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $5, $5.50 and then the pre-market high at $5.94. Beyond $5.94, targets to the upside are $6.80, $7.50 and then $9.31. | Below $4.50, targets to the downside are $4, $3.80, $3.50, $3.10 and then a gap fill at $2.65. | | | | SXTP - Up over 75% in pre after announcing potential human Babesiosis market size for ARAKODA® (tafenoquine): annual max TAM, sales of $245 million; cumulative through patent expiration, $1.1 billion | 60 Degrees Pharmaceuticals, Inc. (SXTP) is a pharmaceutical company focused on developing new medicines for infectious diseases. | In the pre-market this morning, the company announced it has determined the maximum size of the commercial market for ARAKODA® (tafenoquine) for treatment of human babesiosis to be 380,000 patients/$245,000,000 in sales annually, with a cumulative TAM of 1.17 million patients/$1.1 billion through patent expiration in 2035. | Human babesiosis is a serious and debilitating emerging tick-borne illness often found as a co-infection in patients with Lyme Disease. There is a substantial unmet medical need due to the lack of FDA-approved treatments and the frequent generation of resistance associated with repeated use of generic drugs to manage persistent disease. | Three 60 Degrees Pharmaceuticals-sponsored clinical trials (NCT06478641, NCT06207370, NCT06656351) are underway or planned to evaluate tafenoquine's safety and efficacy in treating humans diagnosed with babesiosis. Data are expected from one or more of these studies in the first half of 2026 and will be used as part of a planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration for babesiosis, anticipated in 2026. | Shares of SXTP traded up over 75% in the pre-market in reaction to the news. | | The $2.40 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $2.60, $2.80, $3, $4 and then the the pre-market high at $4.50. | Below $2.40, targets to the downside are $2.30, $2.20, a gap fill at $2.17 and then $2 below that. | | MARKET NEWS 📰 | | | Don't miss out on our MOBILE ALERTS! Some of these alerts have rocketed past the MOON 🌝. Simply text "RAGE" to 1-(888) 487-1534 📲. | *Disclosure: By texting "RAGE" to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn't a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information. | | DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). Full disclaimer: https://bullseyealerts.com/disclaimer/ | SPONSORED CONTENT & COMPENSATION: You should assume we receive compensation for any non-SV purchases through links in this email via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies ("Clients"). We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication. | CLIENT CONTENT: SV is not responsible for any content hosted on Client sites; it is the Client's responsibility to ensure compliance with applicable laws. | NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content, regardless of characterization as "educational," should be considered promotional and subject to disclosed conflicts of interest. Do NOT rely on this as personalized investment advice. SV strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS NOT TYPICAL: Past performance, testimonials, and historical results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Past newsletters, marketing materials, track records, case studies, and promotional content should NOT be relied upon as indication of future performance. Market conditions, regulatory environments, and individual circumstances vary significantly over time. Actual results will vary widely given factors such as experience, skill, risk mitigation practices, market dynamics and capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | REGULATORY STATUS: Neither SV nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. | HIGH-RISK SECURITIES: Securities discussed may be penny stocks, small-cap stocks, cryptocurrencies, options, or other highly speculative investments subject to extreme price volatility, rapid and substantial price movements, limited liquidity, regulatory changes, and potential total loss of value. Market conditions can change rapidly and unpredictably. | LEGAL: In any legal action arising from or related to SV services or these terms, SV shall be entitled to recover attorneys' fees, costs, and disbursements in addition to any other relief. |
|
|
|
Tidak ada komentar:
Posting Komentar